Description
Exact Sciences: Expansion of the Customer Base & Provider Engagement As A Vital Tool For Growth!
Exact Sciences Corporation’s third-quarter 2024 earnings highlighted both achievements and challenges faced by the company. The overall financial performance showed a positive trend with total revenue increasing by 13% year-over-year to $709 million, driven primarily by growth in Cologuard adoption and international expansion of Oncotype DX. The company reported a 75% increase in adjusted EBITDA to $99 million and a record free cash flow of $113 million, signifying a substantial improvement in operational efficiency.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
